Celltium Corporation has been chosen to participate in the 'Market Expansion Type' of the 2022 Small and Medium Enterprise Technology Innovation Development Project, organized by the Ministry of SMEs and Startups. The company will receive research and development funding and will conduct research on discovering treatments for Charcot-Marie-Tooth disease using a high-throughput, large-scale drug screening platform.
Celltium Corporation has received confirmation from the Ministry of Science and ICT for the installation and operation of genetically modified organism (GMO) research facilities within its corporate-a
Celltium Corporation has established animal breeding management and animal experiment facilities within its corporate-affiliated research institute and completed registration as an animal experiment f
Participated by 'Daekyo Investment, Korea Venture Investment, SL Investment', momentum in the non-clinical development of Charcot-Marie-Tooth disease treatment By Reporter Park Dong-woo December 15, 2